<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9862">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830205</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-063</org_study_id>
    <nct_id>NCT01830205</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment</brief_title>
  <official_title>Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of renal function impairment on the single
      dose pharmacokinetics of Daclatasvir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary endpoint is the single dose area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound maximum observed plasma concentrations (CmaxÎ¼) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound area under the plasma concentration-time curve from time zero extrapolated to infinity time [AUC(INF)u] of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound apparent clearance (CLU/F) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery (%UR) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F) of Daclatasvir</measure>
    <time_frame>15 time points up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability endpoints include AEs, serious AEs, AEs leading to discontinuation, deaths, and marked laboratory abnormalities, vital signs and ECG measurements</measure>
    <time_frame>Up to Day 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessments will be based on medical review of adverse event (AE) reports and the results of vital sign measurements, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests. The incidence of observed adverse events will be tabulated and reviewed for potential significance and clinical importance</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A (Normal renal function): Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir 60 mg tablet by mouth single dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (End Stage Renal Disease): Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir 60 mg tablet by mouth single dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (Moderate renal impairment): Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir 60 mg tablet by mouth single dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D (Severe renal impairment): Daclatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir 60 mg tablet by mouth single dose on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>Group A (Normal renal function): Daclatasvir</arm_group_label>
    <arm_group_label>Group B (End Stage Renal Disease): Daclatasvir</arm_group_label>
    <arm_group_label>Group C (Moderate renal impairment): Daclatasvir</arm_group_label>
    <arm_group_label>Group D (Severe renal impairment): Daclatasvir</arm_group_label>
    <other_name>BMS-790052</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Meet renal function criteria in one of four categories

        Exclusion Criteria:

        - Unstable or uncontrolled medical conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 13, 2013</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
